Autifony Therapeutics
Series A in 2015
Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, established in 2011. The company specializes in developing innovative medicines aimed at treating hearing disorders, including hearing loss and tinnitus. In addition to its focus on auditory conditions, Autifony is also involved in drug discovery for central nervous system disorders, addressing challenges related to conditions such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By leveraging its platform, the company seeks to alleviate symptoms associated with these disorders and meet the unmet medical needs of patients.
Karus Therapeutics
Series B in 2012
Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.
Oxagen Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing and commercializing anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company specializes in small molecule drugs that target the CRTH2 receptor, which plays a key role in initiating and maintaining allergic responses. Oxagen's pipeline includes OC000459, an oral CRTH2 antagonist designed for eosinophilic asthma and allergic rhinoconjunctivitis. Additionally, the company addresses various inflammatory diseases such as autoimmune disease, inflammatory bowel disease, psoriasis, allergy, and rheumatoid arthritis. Founded in 1996, Oxagen serves customers globally, including in the United Kingdom, Russia, CIS countries, and other international markets.
Sutro Biopharma
Venture Round in 2007
Sutro Biopharma, Inc. is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary integrated cell-free protein synthesis platform known as XpressCF. Sutro Biopharma’s product candidates include STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, an antibody-drug conjugate directed against folate receptor-alpha for treating ovarian and endometrial cancers. The company has also established collaboration and licensing agreements to advance bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, Sutro Biopharma is dedicated to developing innovative biopharmaceutical solutions.
GlycoFi is a biotech company focused on developing biotherapeutics utilizing glycan optimization technology. Founded in 2000 and based in Lebanon, New Hampshire, the firm specializes in a proprietary protein manufacturing process that employs engineered yeast strains to achieve precise human glycosylation. This innovative approach enables the creation of therapeutic proteins, which are essential for drug development. GlycoFi aims to build its own pipeline of products while also collaborating with other pharmaceutical companies to enhance their drug offerings. In 2006, GlycoFi became a subsidiary of Merck & Co. Inc., further expanding its capabilities in the biotherapeutics field.
Oxagen Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing and commercializing anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company specializes in small molecule drugs that target the CRTH2 receptor, which plays a key role in initiating and maintaining allergic responses. Oxagen's pipeline includes OC000459, an oral CRTH2 antagonist designed for eosinophilic asthma and allergic rhinoconjunctivitis. Additionally, the company addresses various inflammatory diseases such as autoimmune disease, inflammatory bowel disease, psoriasis, allergy, and rheumatoid arthritis. Founded in 1996, Oxagen serves customers globally, including in the United Kingdom, Russia, CIS countries, and other international markets.
Aderis Pharmaceuticals
Series D in 2001
Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cardio-renal diseases. The company focuses on creating novel small-molecule, receptor-specific therapeutics, including adenosine agonists and antagonists, which are designed to diagnose and treat cardiovascular conditions. Additionally, Aderis is developing leukotriene synthesis inhibitors aimed at managing chronic renal disease. The company also has strategic license agreements that involve late-stage products for treating Parkinson's disease and diagnosing coronary artery disease. By targeting specific proteins to either enhance or inhibit their activity, Aderis aims to improve patient outcomes and quality of life while minimizing side effects associated with treatments.
eBioinformatics
Venture Round in 2000
eBioinformatics is a Bioinformatics Service Provider. They deliver innovative and broad-ranging bioinformatics services to the worldwide bioscience research effort. The difficulty of managing the flood of data generated by biomedical and biotechnology research is the inspiration behind eBioinformatics ' products. eBioinformatics emphasises accessibility and usability so that bioscientists, whether they are working in academic, government or corporate research, are empowered by the ability to analyze and manage the large quantities of data they produce.